Table 4.
Disproportionality analysis results for suspected GDD cases of GBCAs in FAERS and VigiBase
| Subgroup | FAERS | VigiBase | ||
|---|---|---|---|---|
| n | ROR025 | n | ROR025 | |
| Gadopentetate dimeglumine | 38 | 425.13 | 168 | 1748.36 |
| Gadobenate dimeglumine | 48 | 1145.87 | 174 | 3246.28 |
| Gadoxetate disodium | 1 | 31.65 | 127 | 5123.18 |
| Gadoterate meglumine | 17 | 775.42 | 20 | 89.38 |
| Gadodiamide | 27 | 707.39 | 157 | 4525.03 |
| Gadoversetamide | 18 | 981.19 | 144 | 18,618.41 |
| Gadoteridol | 5 | 134.05 | 11 | 95.83 |
| Gadobutrol | 74 | 1995.04 | 71 | 323.81 |
ROR reporting odds ratio, GBCAs gadolinium-based contrast agents, GDD gadolinium deposition disease